| Identification | Back Directory | [Name]
1-Hexadecanaminium, N-ethyl-N,N-bis(hydroxymethyl)-, bromide (1:1) | [CAS]
1622060-51-8 | [Synonyms]
BP13944
BP-13944
BP 13944
1-Hexadecanaminium, N-ethyl-N,N-bis(hydroxymethyl)-, bromide (1:1) | [Molecular Formula]
C20H44BrNO2 | [MOL File]
1622060-51-8.mol | [Molecular Weight]
410.48 |
| Hazard Information | Back Directory | [Description]
BP13944 is a potential dengue virus NS2B/NS3 protease inhibitor. | [Uses]
BP13944 is a potential small molecule inhibitor discovered by high-throughput screening. It can effectively inhibit the expression of dengue virus (DENV) replicons with an EC50 value of 1.03±0.09 μM. BP13944 can inhibit the replication or viral RNA synthesis of all four serotypes of DENV, but is ineffective against Japanese encephalitis virus. BP13944 may target the DENV NS3 protease, and the E66G amino acid substitution in the NS3 protease region will cause the virus to become resistant to BP13944. BP13944 has no obvious cytotoxicity. As there is currently no effective dengue vaccine and treatment, BP13944, as an effective small molecule inhibitor, may become a potential agent for the treatment of dengue in the future. | [References]
[1] A Novel Dengue Virus Inhibitor, BP13944, Discovered by High-Throughput Screening with Dengue Virus Replicon Cells Selects for Resistance in the Viral NS2B/NS3 Protease |
|
|